Overview: Current Status of Thrombolytic Therapy in Acute Myocardial Infarction

References to Literature

• Gruppo Italiano per lo studio della streptochinasi nell'infarto, miocardico(gissi) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 1 397–402.
   PubMed Web of Science ®Google Scholar
• Rovelli, F De Vita, C Feruglio, GA GISSI trial: Early results and late follow up. J. Am. Coll. Cardiol. 1987 10 33B–39B.
   PubMed Web of Science ®Google Scholar
• Van de Werf, F Arnold, AER and the European Cooperative Study Group for recombinant tissue type plasminogen activator (RT-PA) Effect of intravenous plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction Br. Med. J.
   Google Scholar
• The isam Study Group A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N. Engl J. Med. 1986 314 1465–1471.
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,189 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988 2 349–360.
   PubMed Web of Science ®Google Scholar
• Wilcox, RG von der Lippe, G Olsson, CG Jenssen, G Skene, AM Hampton, JR Trial of tissue plasminogen activator (rt-PA) for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1988 2 525–530.
   PubMed Web of Science ®Google Scholar
• Kennedy, JW Martin, GV Davis, KB The Western Washington intravenous streptokinase in acute myocardial infarction randomised trial. Circulation 1988 77 345–352.
   Google Scholar
• White, HD Norris, RM Brown, MA Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N. Engl J. Med. 1987 317 850–855.
   PubMed Web of Science ®Google Scholar
• Guerci, AD Gerstenblith, G Brinker, JA A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl J. Med. 1987 317 1613–1618.
   PubMed Web of Science ®Google Scholar
• O'Rourke, M Baron, D Keogh, A Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988 77 1311–1315.
   PubMed Web of Science ®Google Scholar
• Van der Werf, F Arnold, AER and the European Cooperative Study Group for recombinant tissue type plasminogen activator (RT-PA) Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction. Br. Med. J. 1988 297 1374–1379.
   Google Scholar
• Pennica, D Holmes, WE Kohr, WJ Harkins, RN Vehar, GA Ward, CA Bennett, WF Yelverton, E Seeburg, PH Heyneker, HL Goeddel, DV Collen, D Cloning and expression of human tissue-type plasminogen activator cDNA in E coli. mesTPA-recombinant technique. Nature 1983 300 20 214–221.
   Google Scholar
• Gold, HK Fallon, J Yasuda, T Leinbach, R Khaw, B Newell, J Guerrero, J Vislosky, F Hoyng, C Grossbard, E Collen, D Coronary thrombolysis with recombinant human tissue-type plasminogen activator Circulation 1984 70 4 700–707.
   PubMedGoogle Scholar
• Collen, D Topol, EJ Tifenbrunn, AJ Gold, HK Weisfeld, ML Coronary thrombolysis with recombinant human tissue type plasminogen activator: A prospective, randomized, placebo-controlled trial. Circulation 1984 70 1012–1017.
   PubMed Web of Science ®Google Scholar
• The TIMI Study Group The thrombolysis in myocardial infarction (TIMI) trial. Phase I results. N. Engl J. Med. 1985 312 932–936.
   PubMed Web of Science ®Google Scholar
• Magnani, B and the Plasminogen Activator Italian Multicenter Study (paims) Group Comparison of intravenous recombinant single chainhuman tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J. Am. Coll. Cardiol. 1989 13 19–26.
   Google Scholar
• Chesebro, JH Kratterud, G Robert, R Borer, J Cohen, LS Thrombolysis in myocardial infarction (TIMI) trial Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987 76 142–154.
   PubMed Web of Science ®Google Scholar
• Verstraete, M Bernard, R Bory, M Brower, RW Collen, D deBono, DP Erbel, R Huhman, W Lennane, RJ Lubsen, J Mathey, D Meyer, J Michels, HR Rutsch, W Schartl, M Schmidt Uebis, R von Essen, R Randomized trial of intravenous recombinant human tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985 2 842–847.
   Google Scholar
• Verstraete, M Bleifeld, W Brower, RW Charbonnier, B Collen, D de Bono, DP Dunning, AJ Lennane, RJ Lubsen, J Mathey, DG Michel, PL Raynauld, P Schofer, J Vahanian, A van Haecke, J Van de Kley Van de Werf, F Von Essen, R Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985 2 965–969.
   Google Scholar
• Williams, DO Borer, J Braunwald, E James, Chesebro Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: A report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986 73 338–346.
   Google Scholar
• Verstraete, M Bounameaux, H Decock, F Van der Were, F Collen, D Pharmacoinetics and syremic fibrinolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in man. J. Pharmacol. Exp. Therap. 1985 235 506–512.
   PubMed Web of Science ®Google Scholar
• Garabedian, HD Gold, HK Leinbach, RC Johns, JA Yasuda, T Kanke, M Collen, D Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 1987 9 599–607.
   PubMed Web of Science ®Google Scholar
• Garabedian, HD Gold, HK Leinbach, RC Yasuda, T Johns, JA Collen, D Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J. Cardiol. 1986 58 673–679.
   Google Scholar
• Jackson, CV Crowe, VG Craft, TJ Sunboom, JL Grinnell, BW Bobbitt, JL Burck, PJ Quay, JF Smith, GF Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990 82 930–940.
   Google Scholar
• Larsen, GR Timony, GA Horgan, PG Barone, KM Henson, KS Angus, LB Stoudemire, JB Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to Activase J. Biol. Chem. 1991 in press.
   Google Scholar
• Gold, HK Leinbach, RC Garabedian, HD Yasuda, T Johns, JA Gorssbard, EB Palacios, I Collen, D Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion. Circulation 1986 73 2 347–353.
   Google Scholar
• Yasuda, T Gold, HK Fallon, JT Leinbach, RC Garabedian, HD Guerrero, JL Collen, D Canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombosis. J. Am. Coll. Cardiol. 1989 13 1409–1414.
   Google Scholar
• Yasuda, T Gold, HK Leinbach, RC Saito, T Guerrero, JL Jang, IK Holt, R Fallon, JT Collen, D Lysis of rt-PA resistent plateletrich coronary arterial thrombus with combined bolus injection of recombinant tissue-type plasminogen activator (rt-PA) and antiplatelet GPIIb/IIIa antibody. J. Am. Coll. Cardiol. 1990 16 1728–1735.
   PubMed Web of Science ®Google Scholar
• John, JA Gold, HK Leinbach, RC Yasuda, T Gimple, LW Werner, W Finkelstein, D Newell, J Ziskind, A Collen, D Prevention of coronary artery occlusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction: A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation 1988 78 646–556.
   Google Scholar
• Falk, E Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985 72 699–708.
   Google Scholar
• Davies, MJ Thomas, AC Plaque Assuring: The cause of acute myocardial infarction, sudden death, and crescendo angina. Br. Heart J. 1985 53 363–373.
   PubMedGoogle Scholar
• Vetrovec, GW Cowley, MJ Overton, H Richardson, DW Intracoronary thrombus in syndrom of unstable myocardial ischaemia. Am Heart J. 1981 102 1202–1208.
   PubMedGoogle Scholar
• Holmes, DR Jr. Hartzler, GO Smith, HC Fuster, V Coronary artery thrombosis in patients with unstable angina. Br. Heart J. 1981 45 411–416.
   Google Scholar
• Heras, M Chesebro, JH Thompson, PL Fuster, V Prevention of early and late rethrombosis and further strategies after coronary reperfusion. Thrombosis in cardiovascular disease. Marcel Dekker, Inc. NY, NY 1989 203–229.
   Google Scholar
• Chesebro, JH Clements, IP Fuster, V Elvaback, LR Smith, HC A platelet-inhibitor-drug trial in coronary artery bypass operations benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency 1982 307 73–78.
   Google Scholar
• Fuster, V Badimon, L Cohen, M Ambrose, JA Badimon, JJ Chesebro, J Insights into the pathogeneisis of acute ischaemic syndromes. Circulation 1988 77 1213–1220.
   PubMed Web of Science ®Google Scholar
• Fuster, V Stein, B Ambrose, JA Badimon, L Badimon, JJ Chesebro, JH Atherosclerotic plaque rupture and thrombosis evolving concept. Circulation 1990 82 Supp II II-47–II-59.
   Google Scholar
• Sherman, TC Litvack, F Grundfest, W Lee, M Coronary angioscopy in patients with unstable angina pectoris. N. Engl J. Med. 1986 315 913–919.
   PubMed Web of Science ®Google Scholar
• Coller, BS Peerschke, EI Scudder, LE Sullian, CA A murinemonoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 1983 72 325–338.
   PubMed Web of Science ®Google Scholar
• Coller, BS A new murinemonoclonal antibody reports an activation-dependent change in the conformation and of microenvironment of the platelet-GPIIb/IIIa complex. J. Clin. Invest. 1985 76 101–108.
   PubMed Web of Science ®Google Scholar
• Coller, BS Scudder, LE Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody. Blood 1986 66 1456–1459.
   Google Scholar
• Yasuda, T Gold, HK Fallon, JT Leinbach, RC Guerrero, JL Scudder, LE Kankem Shealy, D Ross, MJ Collen, D Coller, BS Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J. Clin. Invest. 1988 81 1284–1291.
   PubMed Web of Science ®Google Scholar
• Gold, HK Coller, BS Yasuda, T Saito, T Fallon, JT Guerrero, JL Leinbach, RC Ziskind, AA Collen, D Rapid and sustained coronary artery recanalization with plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988 77 670–677.
   PubMed Web of Science ®Google Scholar
• Yasuda, T Gold, HK Leinbach, RC Saito, T Guerrero, JL Jang, IK Holt, R Fallon, JT Collen, D Lysis of rt-PA resistant platelet-rich coronary arterial thrombus with combined bolus injection of recombinant tissue-type plasminogen activator (rt-PA) and antiplatelet GPIIIa antibody. J. Am. Coll. Cardiol. in press.
   Google Scholar
• Yasuda, T Gold, HK Leinbach, RC Fallon, JY Effect of reduced heparin on rt-PA thrombolysis during platelet GPIIb/IIIa receptor blockade. Circulation 1990 82 III 276 ( abstract).
   Google Scholar
• Musial, J Nieniarowski, S Rucinsky, B Stewart, GJ Cook, JJ Williams, JA Edmunds, M Inhibition of platelet adhesion to surface of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation 1990 82 261–273.
   PubMedGoogle Scholar
• Yasuda, T Gold, HK Leinbach, RC Yaoita, H Fallon, JT Guerrero, L Napier, MA Bunting, S Collen, D Kistrin, a polypeptide platelet PG IIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activatgor in a canine preparation. Circulation 1991 83 1038–1047.
   PubMed Web of Science ®Google Scholar
• Jang, IK Gold, HK Leinbach, RC Fallon, JT Collen, D In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circulation Research in press.
   Google Scholar
• Yasuda, T Gold, HK Yaoita, H Leinbach, RC Guerrero, JL Jang, IK Holt, R Fallon, JT Collen, D Comparative effects of aspirin, a synthetic thrombin inhibitor, and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J. Am. Coll. Cardiol. 1990 16 3 714–722.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing physician's health study. N. Engl J. Med 1989 321 129–135.
   PubMed Web of Science ®Google Scholar
• Theroux, P Quimet, H McCans, J Latour, JG Aspirin, heparin, or both to treat acute unstable angina. N. Engl J. Med. 1988 319 1106–1111.
   Google Scholar
• Bjork, I Olson, ST Shore, JD Molecular mechanism of the accelerating effect of heparin on the reaction between antithrombin and clotting proteinases. Heparin Lane, DA, Lindahl, UL CRC Press, Inc. Boca Raton, FL 1989 229–255.
   Google Scholar
• Edit, JF Allison, P Noble, S Ashton, S Golino, P McNatt, J Buja, LM Willerson, JT Thrombin in an important mediator of platelet arregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 1989 84 18–27.
   Google Scholar
• Yasuda, T Abraham, SA Pieri, P Katayama, H Evaluation of residual myocardial viability in a patient with acute myocardial infarction. J. Nuc. Med. 1990 31 225–230.
   Google Scholar
• Pieri, P Abraham, SA Katayama, H Yasuda, T Thallium -201 myocardial scintigraphy: Single injection, re-injection, or 24-hour delayed imaging? J. Nuc. Med. 1990 31 1390–1396.
   Google Scholar
• Ohman, EM Califf, RM Topol, EJ Candela, R Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990 82 781–791.
   PubMed Web of Science ®Google Scholar